Insilico Medicine (HKEX: 03696) announced that ISM8969/HT-001, an orally available, blood-brain barrier (BBB)-penetrant NLRP3 inhibitor co-developed with Hygtia Therapeutics Co., Ltd, has received investigational new drug (IND) approval from China's National Medical Products Administration (NMPA) for the treatment of Parkinson's disease. The approval enables parallel clinical evaluation in China alongside an already-initiated Phase I study in Australia, where first-in-human dosing was completed in June 2026.
The NMPA approval follows US FDA IND clearance granted in January 2026, giving ISM8969/HT-001 regulatory authorization to proceed in two major markets simultaneously. The Phase I study is a randomized, double-blind, placebo-controlled trial evaluating safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) in healthy subjects, with an additional arm assessing preliminary efficacy in Parkinson's disease patients.
Parkinson's disease has no approved disease-modifying therapies, making neuroinflammation an increasingly active area of drug development. ISM8969/HT-001 selectively inhibits the NLRP3 inflammasome, a multiprotein complex that activates caspase-1 and drives release of pro-inflammatory cytokines including IL-1β and IL-18. Its defining characteristic relative to other NLRP3 inhibitors in clinical development is BBB penetrance, enabling direct engagement with neuroinflammatory pathways in the central nervous system (CNS). The company said preclinical studies demonstrated favorable in vitro activity and safety, a robust in vivo PK/PD profile, and efficacy in multiple mouse models of both acute and chronic inflammation. ISM8969/HT-001 was discovered using Insilico Medicine's generative AI-based drug design platform, Chemistry42, and was nominated as a preclinical candidate in December 2024 — reaching first-in-human dosing approximately 18 months later.
The competitive landscape for NLRP3 inhibition is active but largely peripherally restricted. Most NLRP3 inhibitors in clinical development are intended for peripheral inflammatory diseases rather than CNS disorders, making BBB penetration a distinguishing feature of ISM8969/HT-001. In the broader Parkinson's disease pipeline, disease-modification efforts are concentrated in alpha-synuclein antibodies such as Roche's prasinezumab, GLP-1 receptor agonists including Novo Nordisk's semaglutide in the SPARK-PD trial, and cell therapy programs such as BlueRock Therapeutics' bemdaneprocel, now in Phase III. None of these share ISM8969/HT-001's mechanistic rationale of direct CNS inflammasome inhibition.